《再鼎医药Zai Lab Limited（ZLAB）2025年第三季度财报（10-Q）「NASDAQ」（英文版）（76页）.pdf》由会员分享，可在线阅读，更多相关《再鼎医药Zai Lab Limited（ZLAB）2025年第三季度财报（10-Q）「NASDAQ」（英文版）（76页）.pdf（76页珍藏版）》请在三个皮匠报告上搜索。

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,DC 20549_FORM 10-Q_(Mark One)QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 19For the quarterly period ended September 30,2025ORTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT

2、 OF 19For the transition period from _ to _Commission File Number:001-38205_ZAI LAB LIMITED(Exact Name of Registrant as Specified in its Charter)_Cayman Islands98-1144595(State or Other Jurisdiction of Incorporation or Organization)(I.R.S.Employer Identification No.)899 Halei RoadBuilding B,PudongSh

3、anghaiChina201203314 Main Street 4th Floor,Suite 100 Cambridge,MA,USA02142(Address of Principal Executive Offices)(Zip Code)+86 216163 2588+1 857 706 2604(Registrants Telephone Number,Including Area Code)_Securities registered pursuant to Section 12(b)of the Act:Title of each classTradingSymbol(s)Na

4、me of each exchangeon which registeredAmerican Depositary Shares,each representing 10 OrdinaryShares,par value$0.000006 per shareZLABThe Nasdaq Global MarketOrdinary Shares,par value$0.000006 per share*9688The Stock Exchange of Hong Kong Limited*Included in connection with the registration of the Am

5、erican Depositary Shares with the Securities and Exchange Commission.The ordinary shares arenot registered or listed for trading in the United States but are listed for trading on The Stock Exchange of Hong Kong Limited.Indicate by check mark whether the registrant(1)has filed all reports required t

6、o be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934during the preceding 12 months(or for such shorter period that the registrant was required to file such reports),and(2)has been subject to such filingrequirements for the past 90 days.Yes No Indicate by check mark whether the reg